Histone Deacetylase Inhibitors: Emerging Markets

Histone Deacetylase Inhibitors: Emerging Markets

  • February 2014 •
  • 153 pages •
  • Report ID: 2042687 •
  • Format: PDF

The global histone deacetylase inhibitor (HDI) market reached $153 million in 2011 and $223.2 million in 2012. This market is expected to be valued at $361.8 million in 2013 and $954.3 million by 2018, a compound annual growth rate (CAGR) of 21.4%.

This report provides:
An overview of the global market for histone deacetylase inhibitors.
Analyses of global market trends, with data from 2011 and 2012, estimates for 2013, and projections of CAGRs through 2018.
A breakdown of the market for histone deacetylase inhibitors not only by region, but by application as well.
Information pertaining to the manufacturing of HDIs as well information on the manufacturing companies involved.
Profiles of leading HDI companies in the market.


The objective of this BCC Research study was to evaluate, analyze and predict the prospective histone deacetylase inhibitors (HDIs) market, as well as the progress of the ongoing clinical developments of numerous candidates. The report portrays the present HDI niche market and projects a provisional picture of future market escalation derived from the current products, the impressive HDI pipelines, successful research and development activities, the strategic plans of larger biopharmaceuticals and pharmaceuticals, and the present and prospective market dynamics.The report presents a holistic view on the present market size based on the two approved HDI products: vorinostat (Zolinza) and romidepsin (Istodax). It also interprets the anticipated market size, revenue assessment, prospective products based on classic and second-generation histone deacetylase inhibitors, market leaders, market shares and the drivers shaping the HDIs market. An outline of the innovative platforms, technologies and prospective candidates for the present and potential market based on their potency in various diseases are detailed. It is too early to project the market trend from just two approved products, so the prospective market is presented in a summarized manner derived from the successful and promising clinical developments of late-stage products. The opportunities, limitations, patent analysis, new developments and regulatory aspects are detailed to the extent of the scope of this report. Profiles of reputed and budding companies involved in the development of HDIs are also provided.The sales data for the two products is obtained from the relevant sources, including the manufacturing company’s annual reports. The data is analyzed for the period from 2011 through October 2013. A 2018 revenue projection is also provided. The report analyzes the regional sales data for North America, which is comprised of the U.S. and Canada; Europe; and the emerging markets for this period.


Drugs that target epigenetic alterations have recently presented clinical potential, and histone deacetylase inhibitors comprised one such genre of drugs. The prospect of using histone deacetylase inhibitors in the treatment of cancer is already recognized through vorinostat and romidepsin. The potency and efficacy of these drugs and other candidates for various diseases, including cancer, heart ailments and human immunodeficiency virus (HIV) infection, are being investigated. The progress in the research and development (R&D) of the histone deacetylase inhibitors in recent years is significant. This report offers a synopsis of the latest exploratory work and market opportunities for the producers of HDIs from the viewpoint of new products, their prospective application on target diseases, the latest clinical developments and late-stage candidates. Furthermore, it provides details of scientific researches that would be helpful for scientists and research organizations for the advancement of their R&D work.The present market dynamics including the prospective pipeline, collaboration and joint ventures, focused researches and most importantly the need of drugs for the fatal diseases such as cancer, neurodegenerative diseases and others are driving the activities in the histone deacetylase inhibitors space. There is enormous opportunity for this industry to develop and commercialize products for a huge patient base worldwide and this report presents the details meticulously.


This report accentuates two major aspects. One is the inevitability of histone deacetylase inhibitors to treat diseases, most of which currently have no proper cure. The other is the opportunity in a market that lacks very few commercialized products. There are currently only four drugs approved in the epigenetic drug market. This study presents the key developments of the histone deacetylase inhibitors industry that would be useful for the manufacturers, producers, researchers, research universities, and other government and non-government organizations.


BCC Research carried out the market assessment of the present niche market for histone deacetylase inhibitors, the geographic breakdown of sales data, current and prospective applications, regulatory aspects, market projection, advances and restraints, patent analysis, clinical developments, market leaders and market share for histone deacetylase inhibitors.The sales data for the global markets is authenticated for the present and anticipated values through statistical analysis. Correspondingly, regional data was measured for respective regions. The product and candidate information, technologies and platforms are based on their prospective application and practicability.


BCC Research collected all pertinent information for this study through primary and secondary research methodologies. In the process, BCC Research interviewed industry experts, including producers of histone deacetylase inhibitors, scientists and other industry veterans. Searches were conducted in various information sources. Market projections echo the probable unit prices, usage of HDIs, the present-day economy and plausible HDI applications.